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NOTES A N D COMMENTS

Betaprone Sterilization of Hepatitis-infected Materials
Safety Precautions for Laboratory Workers
Gerald A. LoGrippo, M.D.,* Hajime Hayashi, Ph.D.,* and
Sheikh M . Saeed, M.D.*
The risks of virus hepatitis to laboratory personnel handling HAA-positive
serum prompts us to relate our experiences in this regard. The cold sterilization process using Betaprone (specially
purified grade of betapropiolactone,
BPL) with or without ultraviolet irradiation is advantageous over the heating
procedure (60° C/10 hours) when heat
labile serum components are essential
for fractionation and purification
studies.1Virus hepatitis with jaundice and
transient Australia antigenemia occurred in one of two technicians working for 18 months in the hospital blood
donor station. The two technicians did
not use BPL-treated materials in their
daily screening tests for Australia antigenemia among blood donors. In contrast, hepatitis (icteric or anicteric by
periodic laboratory tests of all personnel) has not occurred among the 17
technicians working in the Immunology
and Virology Laboratory where they
have been handling known and unknown hepatitis-infected sera screened
for HAA and its antibody. Sera came
from 407 known hepatitis patients
with jaundice, 30,000 hospital admissions, and 205 HAA-positive sera for
various studies. Since 1967, the virology and immunochemistry sections
have handled large volumes of HAA-

positive sera for fractionation, purification, and serologic studies. All materials used in this laboratory and known
to be hepatitis-infected have been
treated with BPL prior to handling.
Betaprone (0.35%) and ultraviolet
irradiation process have been used for
plasma'*-^ and serum"' for intravenous
administration in man without clinical
icteric hepatitis. Virus-infected materials, treated by the combined procedure (BPL plus UV), is safe to handle
and is hepatitis-free, as proven clinically in over 200,000 transfusions in
man.--^-" When the combined procedure cannot be employed, Betaprone
treatment of serum without ultraviolet
irradiation is superior to no treatment
in reducing the hepatitis risk for laboratory workers. Treatment of serum by
Betaprone alone is a simpler procedure
and is recommended in lieu of no treatment of infected materials. This simple
procedure has been used in our Immunology and Virology Laboratory
since 1967 without the occurrence of
hepatitis among our 17 technicians.
The immunoelectrophoresis patterns
in Figure 1 emphasize the importance
of pH control of serum or plasma during the BPL treatment process.^-^'^ In
Figure 1, both troughs contain antihuman whole serum. The middle immunoelectrophoretic patterns demonstrate the normal untreated serum
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Figure 1

Betaprone treatment of HAA-positive serum effects of pH control in treatment.

The initial addition of NaOH to serum
(without pH control) followed by the
desired amount of BPL will cause physical-chemical changes in the serum
proteins that give altered electrophoretic mobility patterns.
Betaprone treatment of serum or
plasma does not alter the H A A or its
antibody for serologic tests (immunoprecipitation, counter-electrophoresis,
or CF). Technical details are omitted
here because they have been published elsewhere.

sample. The upper electrophoretic pattern illustrates the results of the same
serum sample treated with 0.4% of
Betaprone when the rate of BPL hydrolysis is pH controlled between pH
6.8 and pH 7.4 with 1 N NaOH. This
is the recommended method inasmuch
as the physical-chemical properties of
serum components are not significantly
altered. 1 The lower electrophoretic pattern shows the effects of 0.4% Betaprone treatment on the serum proteins
by adding NaOH (mol per mol equivalent for Betaprone) before Betaprone.
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